China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corpora...( HAIKOU CITY China Nov. 7 /Xinhua-...),Health

HAIKOU CITY, China, Nov. 7 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets generic and branded speciality pharmaceutical products in China, today announced financial results for the quarter ended September 30, 2008.

Financial Highlights

-- 3Q08 Revenue of $12.6 Million, up 52.0% Year-over-Year

-- $35.6 Million Revenue for nine months ended September 30, up 47.76%

versus same period in 2007

-- 3Q08 Net Income up 37.8% Year-over-Year; up 42.05% in nine months ended

September 30 versus same period in 2007

-- 3Q08 Diluted EPS $0.10 versus 3Q07 Diluted EPS $0.08

-- Diluted EPS $0.32 versus Diluted EPS $0.24 for nine months ended

September 30, 2008 and 2007, respectively

-- 3Q08 Sales of PuSenOK(TM), China's first and only generic version of

Aleve-D(R), Up 124.2% Year-over-Year

Recent and Upcoming Events

-- Clinical Trials of Novel Antibiotic Combination Approved by SFDA and

Initiated

-- AMEX Listing Plans Underway

-- Two-Week U.S. Tour in November 2008 to Present at Conferences and Meet

Investors

Revenue for the third quarter of 2008 increased 52.05% to $12.61 million, compared to $8.29 million in the same period of 2007 and above management's prior guidance for revenue growth of 40%-45%. The increase reflected the expansion of marketing and promotional activities aimed at increasing the sales of existing products, in addition to the Company's increase in pharmaceutical market share from the introduction of new products. Top contributors to the increase in revenue were the Company's branded product PuSenOK(TM), the first and only generic version of Aleve-D(R) available in China; Buflomedil, a treatment for peripheral blood vessel diseases; Roxithromycin dispersible tablet, a macrolide antibiotic; and Bumetanide, a diuretic approved b
'/>"/>